11 – 20 of 55
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
The Urothelial Transcriptomic Response to Interferon Gamma : Implications for Bladder Cancer Prognosis and Immunotherapy
(
- Contribution to journal › Article
-
Mark
The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma
(
- Contribution to journal › Article
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
- 2021
-
Mark
multiclassPairs: An R package to train multiclass pair-based classifier
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
When the Molecular Subtype Is Hidden Behind a Veil of Stroma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight
(
- Contribution to journal › Article
- 2020
-
Mark
Re : A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048
(
- Contribution to journal › Letter
-
Mark
Recurring urothelial carcinomas show genomic rearrangements incompatible with a direct relationship
(
- Contribution to journal › Article
-
Mark
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma
(
- Contribution to journal › Article